Attivare Therapeutics, a Harvard startup out of the Wyss Institute, has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS), Dana-Farber Cancer Institute, and Massachusetts General Hospital. This technology creates an in vivo training ground for the immune system to fight cancer more effectively and prevent infection.

New printing method creates branching vessels in heart tissue that replicate the structure of human vasculature in vitro.

Northpond-funded Laboratory for Bioengineering Research and Innovation makes its fourth investment into the future of biotech.

Researchers develop implantable device that can record a collection of individual neurons over months.